$2.80
Today
as of Jul 22, 16:47 ET
Last 30 days
Recent Press Releases & News
Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
Cellectis Says Phase 1 Lasme-cel Study Shows 100% Response Rate in B-Cell Leukemia Patients
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
Overview
52-week range
$1.33
$5.48
35% of range
Avg surprise (last 0)
—
Avg reaction (last 2)
-0.5%
50% positive
Latest IV / EM
468%
EM ±107.1% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 11, 2026 | Mar/2026 | $-0.18 | — | — | 0.0% | +3.4% | earnings |
| Mon Aug 4, 2025 | Jun/2025 | $-0.24 | — | — | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.18 | — | — | — | -4.4% | earnings |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 3, 2026 | Jun/2026 | OTHER | — | -$0.24 |